HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NACDS Total Store Expo In Brief: Pharmavite, i-Health, AllergEase, Xcentrika, Perfecta

This article was originally published in The Tan Sheet

Executive Summary

Pharmavite offers new VitaMelts, gummies; i-Health expands menopause relief; AllergEase has sweet relief; Novarnica sprays pain relief; Mederma PM lessens scars at night; Perfecta moves into pain relief; Hyland’s extends Defend, repackages 4Kids; B’IOTA combats thinning locks; and Manuka delivers antibacterial properties.

You may also be interested in...



P&G Ventures Startup Incubator Yields Supplements For Menopause Symptoms

P&G Ventures startup's partnership with venture capital group M13 delivered its first brand, the Kindra four-product, hormone-free menopausal line. Kindra says its products provide relief from the seven symptoms of menopause in a market largely neglected.

J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores

J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.

Ensuring Leading Position For GSK Consumer Products Touted In Management Shift

GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS124298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel